Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Jacobs Levy Equity Management Inc. boosted its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 104.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 993,046 shares of the company's stock after acquiring an additional 507,453 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.81% of Mersana Therapeutics worth $1,877,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Verition Fund Management LLC grew its holdings in shares of Mersana Therapeutics by 11,695.2% during the 3rd quarter. Verition Fund Management LLC now owns 1,303,249 shares of the company's stock worth $2,463,000 after purchasing an additional 1,292,200 shares in the last quarter. HealthInvest Partners AB lifted its position in Mersana Therapeutics by 191.3% in the third quarter. HealthInvest Partners AB now owns 538,621 shares of the company's stock worth $1,018,000 after purchasing an additional 353,721 shares during the period. Squarepoint Ops LLC acquired a new stake in Mersana Therapeutics during the second quarter worth $508,000. GSA Capital Partners LLP increased its holdings in Mersana Therapeutics by 368.9% in the 3rd quarter. GSA Capital Partners LLP now owns 271,774 shares of the company's stock valued at $514,000 after buying an additional 213,814 shares during the period. Finally, Federated Hermes Inc. raised its stake in shares of Mersana Therapeutics by 105,301.7% in the 2nd quarter. Federated Hermes Inc. now owns 185,507 shares of the company's stock valued at $373,000 after buying an additional 185,331 shares in the last quarter. 93.92% of the stock is currently owned by institutional investors.

Mersana Therapeutics Price Performance

NASDAQ MRSN traded up $0.21 on Friday, hitting $2.53. 663,225 shares of the company were exchanged, compared to its average volume of 1,366,801. Mersana Therapeutics, Inc. has a 1-year low of $1.22 and a 1-year high of $6.28. The company has a market cap of $312.54 million, a P/E ratio of -4.15 and a beta of 1.40. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. The firm has a 50 day moving average of $2.13 and a two-hundred day moving average of $1.97.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last released its earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $12.60 million during the quarter, compared to analysts' expectations of $7.53 million. During the same period last year, the firm earned ($0.35) EPS. The business's revenue for the quarter was up 63.6% on a year-over-year basis. On average, equities analysts predict that Mersana Therapeutics, Inc. will post -0.61 EPS for the current year.

Insider Buying and Selling

In other Mersana Therapeutics news, CEO Martin H. Jr. Huber sold 50,423 shares of Mersana Therapeutics stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $1.76, for a total transaction of $88,744.48. Following the completion of the sale, the chief executive officer now owns 116,327 shares of the company's stock, valued at approximately $204,735.52. The trade was a 30.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 70,849 shares of company stock worth $129,184 over the last three months. 11.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MRSN shares. Robert W. Baird lowered their target price on shares of Mersana Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 14th. Citigroup began coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a "buy" rating and a $5.00 target price for the company. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $6.00.

Mersana Therapeutics Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.